ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

ClinicalTrials.gov ID: NCT00510068

Public ClinicalTrials.gov record NCT00510068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)

Study identification

NCT ID
NCT00510068
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
410 participants

Conditions and interventions

Interventions

  • Everolimus Drug
  • Everolimus Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2007
Primary completion
Jan 31, 2010
Completion
Feb 28, 2014
Last update posted
Jun 30, 2015

2007 – 2014

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
23
Facility City State ZIP Site status
University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2) Mobile Alabama 36688
Pacific Cancer Medical Center, Inc. Anaheim California 92801
Cedars Sinai Medical Center SC-2 Los Angeles California 90048
University of California at Los Angeles UCLA (3) Los Angeles California 90095
University of California San Francisco Dept. of UCSF Comp. Cancer San Francisco California 94143-0128
Kaiser Permanente Northwest Franklin Medical Offices Denver Colorado
H. Lee Moffitt Cancer Center & Research Institute Malignant Hematology Clinic Tampa Florida 33612
Indiana University Health Goshen Center for Cancer Dept. of Indiana Univ. Cancer Indianapolis Indiana 46202
University of Iowa Medical Center Dept. of Iowa Medical Center Iowa City Iowa 52242
University of Louisville / James Graham Brown Cancer Center SC Louisville Kentucky 40202
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Dept. of Neuroendocrine Clinic New Orleans Louisiana 70115
Boston Medical Center BMC Boston Massachusetts 02118
Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (4) Detroit Michigan 48201
Mayo Clinic - Rochester Rochester Minnesota 55905
Littleton Regional Hospital Dept. of Hematology/Oncology Littleton New Hampshire 03561
Columbia University Medical Center- New York Presbyterian Dept. of Columbia Med. Center New York New York 10032
Levine Cancer Institute Charlotte North Carolina 28203
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept. of OHSU Medical Center Columbus Ohio 43210
Oregon Health & Science University Dept. of OHSU (3) Portland Oregon 97239
St. Luke's Hospital and Health Network St. Luke's Cancer Network Bethlehem Pennsylvania
Fox Chase Cancer Center Philadelphia Pennsylvania 19111-2497
University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania 15213
The Center for Cancer and Blood Disorders Fort Worth Texas 76104
University of Texas/MD Anderson Cancer Center Dept of MD Anderson CancerCent Houston Texas 77030-4009

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00510068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 30, 2015 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00510068 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →